1. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients
- Author
-
Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg Larsen, Jannik, Matos, Olga, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Cordonnier, Catherine, Maertens, Johan, Bretagne, Stã©phane, Agrawal, Samir, Kibbler, Christopher, Pagliuca, Antonio, Ward, Katherine, Akova, Murat, Herbrecht, Raoul, Mallet, Vincent, Ribaud, Patricia, Aljurf, Mahmoud, Averbuch, Dina, Engelhard, Dan, Berg, Thomas, Cornely, Oliver, Penack, Olaf, van Boemmel, Florian, von Lilienfeld Toal, Marie, Blennow, Ola, Ljungman, Per, Bruggemann, Roger, Donnelly, Peter, Kullberg, Bart Jan, Melchers, Willem, Calandra, Thierry, Hirsch, Hans, Marchetti, Oscar, Orasch, Christina, Tissot, Frederic, Castagnola, Elio, Girmenia, Corrado, Mikulska, MALGORZATA KAROLINA, Pagano, Livio, Viscoli, Claudio, De La Camara, Rafael, Duarte, Rafael, Munoz, Patricia, Drgona, Lubos, Hargreaves, Ruth, Hubacek, Petr, Kouba, Michal, Racil, Zdenek, Klyasova, Galina, Pettrikos, George, Roilides, Emmanuel, Skiada, Anna, Rizzi Puechal, Valã©rie, Sinko, Janos, Slavin, Monica, Styczynski, Jan, Tweddle, Lorraine, Wood, Craig, Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire (CNRMA), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Université de Lausanne = University of Lausanne (UNIL), Université Catholique de Louvain = Catholic University of Louvain (UCL), Radboud University [Nijmegen], Rigshospitalet [Copenhagen], Copenhagen University Hospital, Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Università degli studi di Verona = University of Verona (UNIVR), Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Julius Maximilians University Wurzburg, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Department of Hematology, University Hospital Gasthuisberg [Leuven], The ECIL-5 meeting was supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck, and Pfizer, Université de Lausanne (UNIL), Radboud university [Nijmegen], G.B. Rossi Hospital, Verona University, University Hospital Gasthuisberg, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Julius-Maximilians-Universität Würzburg (JMU)
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,030106 microbiology ,Dapsone ,Pneumocystis carinii ,03 medical and health sciences ,Immunocompromised Host ,0302 clinical medicine ,Diagnostic Tests ,Internal medicine ,medicine ,Pneumocistis jirovecii ,Humans ,Routine ,Pharmacology (medical) ,030212 general & internal medicine ,Intensive care medicine ,Pharmacology ,Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17] ,business.industry ,Diagnostic Tests, Routine ,Pneumocystis ,Pneumonia, Pneumocystis ,Pneumonia ,medicine.disease ,Trimethoprim ,Transplant Recipients ,3. Good health ,Fludarabine ,Regimen ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Infectious Diseases ,Hematologic Neoplasms ,Alemtuzumab ,Rituximab ,business ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Pentamidine ,medicine.drug ,immunocompromised host, pneumonia, Pneumocistis jirovecii ,Stem Cell Transplantation - Abstract
Item does not contain fulltext The Fifth European Conference on Infections in Leukaemia (ECIL-5) convened a meeting to establish evidence-based recommendations for using tests to diagnose Pneumocystis jirovecii pneumonia (PCP) in adult patients with haematological malignancies. Immunofluorescence assays are recommended as the most sensitive microscopic method (recommendation A-II: ). Real-time PCR is recommended for the routine diagnosis of PCP ( A-II: ). Bronchoalveolar lavage (BAL) fluid is recommended as the best specimen as it yields good negative predictive value ( A-II: ). Non-invasive specimens can be suitable alternatives ( B-II: ), acknowledging that PCP cannot be ruled out in case of a negative PCR result ( A-II: ). Detecting beta-d-glucan in serum can contribute to the diagnosis but not the follow-up of PCP ( A-II: ). A negative serum beta-d-glucan result can exclude PCP in a patient at risk ( A-II: ), whereas a positive test result may indicate other fungal infections. Genotyping using multilocus sequence markers can be used to investigate suspected outbreaks ( A-II: ). The routine detection of dihydropteroate synthase mutations in cases of treatment failure is not recommended ( B-II: ) since these mutations do not affect response to high-dose co-trimoxazole. The clinical utility of these diagnostic tests for the early management of PCP should be further assessed in prospective, randomized interventional studies.
- Published
- 2016